Protection against oncogenic non-vaccine types (cross-protection) offered by human
papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical …

We previously reported higher anti-HPV-16 and-18 immune responses induced by HPV-
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …

In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …

The observer-blind, randomized, age-stratified, head-to-head study (NCT00423046)
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …

The majority of human papillomavirus (HPV) belong to the genus alpha-papillomavirus,
which can be further subdivided into species and then strains. Approximately 200 strains of …

Individuals infected with human immunodeficiency virus (HIV) have excess risk of
developing human papillomavirus (HPV)-related disease. A substantial fraction of HPV …

Abstract In the Phase III PATRICIA study (NCT00122681), the human papillomavirus (HPV)‐
16/18 AS04‐adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) was highly …

Human papillomavirus (HPV) is the most common sexually transmitted infection, with 15
HPV types related to cervical, anal, oropharyngeal, penile, vulvar, and vaginal cancers …

Background: Previous analyses from a randomised trial in women aged 24–45 years have
shown the quadrivalent human papillomavirus (qHPV) vaccine to be efficacious in the …

Human papillomavirus (HPV) is a major causative agent of anogenital warts and a
necessary cause of cervical cancer. This report will serve to assess the safety and …